Skip to content
Screener

Corcept Therapeutics CORT Operating Lease Liabilities

Operating Lease Liabilities at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$30.54M-5.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$41.32M-6.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.41M+1,024%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$60.63M-22.8%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$5.92M+30.9%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemJune 30,2026December 31,2025
Accrued and other liabilities115,34790,603
Short-term operating lease liability1,9171,084
Total current liabilities153,802166,085
Long-term operating lease liability7,5045,023
Long-term accrued government rebates6,1322,562
Long-term accrued income taxes15,48815,176
Total liabilities182,926188,846
Commitments and contingencies (Note 4)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's operating lease liabilities?
Corcept Therapeutics (CORT) reported operating lease liabilities of $7.5M in Q2 2026.
How has Corcept Therapeutics's operating lease liabilities changed year-over-year?
Corcept Therapeutics's operating lease liabilities increased by 34.3% year-over-year, from $5.59M to $7.5M.
What is the long-term trend for Corcept Therapeutics's operating lease liabilities?
Over 4 years (2020 to 2025), Corcept Therapeutics's operating lease liabilities has grown at a 77.9% compound annual growth rate (CAGR), from $501K to $5.02M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Corcept Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude